Literature DB >> 32723572

The Influence of Cost Information on Treatment Choice: A Mixed-Methods Study.

Thompson Zhuang1, Joost T P Kortlever2, Lauren M Shapiro1, Laurence Baker3, Alex H S Harris4, Robin N Kamal5.   

Abstract

PURPOSE: To test the null hypothesis that exposure to societal cost information does not affect choice of treatment for carpal tunnel syndrome (CTS).
METHODS: We enrolled 304 participants using the Amazon Mechanical Turk platform to complete a survey in which participants were given the choice between carpal tunnel release (CTR) or a less-expensive option (orthosis wear) in a hypothetical mild CTS scenario. Patients were randomized to receive information about the societal cost of CTR (cost cohort) or no cost information (control). The primary outcome was the probability of choosing CTR measured on a 6-point ordinal scale. We employed qualitative content analysis to evaluate participants' rationale for their choice. We also explored agreement with various attitudes toward health care costs on an ordinal scale.
RESULTS: Participants in the cost cohort exhibited a greater probability of choosing surgery than those in the control cohort. The relative risk of choosing surgery after exposure to societal cost information was 1.43 (95% confidence interval, 1.11-1.85). Among participants who had not previously been diagnosed with CTS (n = 232), the relative risk of choosing surgery after exposure to societal cost information was 1.55 (95% confidence interval, 1.17-2.06). Lack of personal monetary responsibility frequently emerged as a theme in those in the cost cohort who chose surgery. The majority (94%) of participants expressed at least some agreement that health care cost is a major problem whereas only 58% indicated that they consider the country's health care costs when making treatment decisions.
CONCLUSIONS: Participants who received societal cost information were more likely to choose the more expensive treatment option (CTR) for mild CTS. CLINICAL RELEVANCE: Exposure to societal cost information may influence patient decision making in elective hand surgery. A complete understanding of this influence is required prior to implementing processes toward greater cost transparency for diagnostic/treatment options. Sharing out-of-pocket costs with patients may be a beneficial approach because discussing societal cost information alone will likely not improve value of care.
Copyright © 2020 American Society for Surgery of the Hand. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Carpal tunnel release; carpal tunnel syndrome; decision making; societal cost

Year:  2020        PMID: 32723572      PMCID: PMC8139279          DOI: 10.1016/j.jhsa.2020.05.019

Source DB:  PubMed          Journal:  J Hand Surg Am        ISSN: 0363-5023            Impact factor:   2.230


  41 in total

1.  Shared decision making--pinnacle of patient-centered care.

Authors:  Michael J Barry; Susan Edgman-Levitan
Journal:  N Engl J Med       Date:  2012-03-01       Impact factor: 91.245

2.  Can Appealing to Patient Altruism Reduce Overuse of Health Care Services? An Experimental Survey.

Authors:  Kevin R Riggs; Peter A Ubel; Brendan Saloner
Journal:  J Gen Intern Med       Date:  2017-02-02       Impact factor: 5.128

3.  NHS proposes to stop funding 17 "unnecessary" procedures.

Authors:  Gareth Iacobucci
Journal:  BMJ       Date:  2018-07-02

4.  Cost-Minimization Analysis of Open and Endoscopic Carpal Tunnel Release.

Authors:  Steven Zhang; Molly Vora; Alex H S Harris; Laurence Baker; Catherine Curtin; Robin N Kamal
Journal:  J Bone Joint Surg Am       Date:  2016-12-07       Impact factor: 5.284

5.  More Is Not Always Better: Intuitions About Effective Public Policy Can Lead to Unintended Consequences.

Authors:  Ellen Peters; William Klein; Annette Kaufman; Louise Meilleur; Anna Dixon
Journal:  Soc Issues Policy Rev       Date:  2013-01-01

6.  Reference-based benefit design changes consumers' choices and employers' payments for ambulatory surgery.

Authors:  James C Robinson; Timothy Brown; Christopher Whaley
Journal:  Health Aff (Millwood)       Date:  2015-03       Impact factor: 6.301

7.  Health Care Price Transparency and Communication: Implications for Radiologists and Patients in an Era of Expanding Shared Decision Making.

Authors:  Gelareh Sadigh; Ruth C Carlos; Elizabeth A Krupinski; Carolyn C Meltzer; Richard Duszak
Journal:  AJR Am J Roentgenol       Date:  2017-07-25       Impact factor: 3.959

8.  Increases in consumer cost sharing redirect patient volumes and reduce hospital prices for orthopedic surgery.

Authors:  James C Robinson; Timothy T Brown
Journal:  Health Aff (Millwood)       Date:  2013-08       Impact factor: 6.301

9.  Splinting vs surgery in the treatment of carpal tunnel syndrome: a randomized controlled trial.

Authors:  Annette A M Gerritsen; Henrica C W de Vet; Rob J P M Scholten; Frits W Bertelsmann; Marc C T F M de Krom; Lex M Bouter
Journal:  JAMA       Date:  2002-09-11       Impact factor: 56.272

10.  Patient-oncologist cost communication, financial distress, and medication adherence.

Authors:  Christine M Bestvina; Leah L Zullig; Christel Rushing; Fumiko Chino; Gregory P Samsa; Ivy Altomare; James Tulsky; Peter Ubel; Deborah Schrag; Jon Nicolla; Amy P Abernethy; Jeffrey Peppercorn; S Yousuf Zafar
Journal:  J Oncol Pract       Date:  2014-05       Impact factor: 3.840

View more
  2 in total

1.  Evaluation of the Reliability and Quality of Information in Carpal Tunnel Syndrome Shared on YouTube.

Authors:  Emre Anıl Özbek; Mehmet Armangil; Mustafa Onur Karaca; Abdullah Merter; Merve Dursun; Hakan Kocaoğlu
Journal:  J Wrist Surg       Date:  2021-09-06

Review 2.  Effectiveness of Conservative Treatment According to Severity and Systemic Disease in Carpal Tunnel Syndrome: A Systematic Review.

Authors:  Mar Hernández-Secorún; Raquel Montaña-Cortés; César Hidalgo-García; Jacobo Rodríguez-Sanz; Jaime Corral-de-Toro; Sofia Monti-Ballano; Sami Hamam-Alcober; José Miguel Tricás-Moreno; María Orosia Lucha-López
Journal:  Int J Environ Res Public Health       Date:  2021-02-28       Impact factor: 3.390

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.